<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03212781</url>
  </required_header>
  <id_info>
    <org_study_id>IDAO</org_study_id>
    <nct_id>NCT03212781</nct_id>
  </id_info>
  <brief_title>Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women</brief_title>
  <official_title>Total Dose Infusion of Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Iron deficiency is the most prevalent nutritional deficiency and the most common cause of&#xD;
      anemia .It is characterized by a defect in hemoglobin synthesis, resulting in red blood cells&#xD;
      that are abnormally small (microcytic) and contain a decreased amount of hemoglobin&#xD;
      (hypochromic).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in Hemoglobin concentration from baseline to 8 weeks therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>measure hemoglobin level before and after treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>intravenous iron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive intravenous iron as total dose infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>oral iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive oral iron</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron dextran</intervention_name>
    <description>total dose infusion</description>
    <arm_group_label>intravenous iron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Fumarate</intervention_name>
    <description>oral tablets</description>
    <arm_group_label>oral iron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hemoglobin &lt; 10 g/dL&#xD;
&#xD;
          -  Gestational age between 14-28 weeks.&#xD;
&#xD;
          -  Willingness to participate and signing the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Iron overload or disturbances in utilization of iron&#xD;
&#xD;
          -  Decompensated liver cirrhosis and active hepatitis&#xD;
&#xD;
          -  Active acute or chronic infections&#xD;
&#xD;
          -  History of multiple allergies&#xD;
&#xD;
          -  Known hypersensitivity to parenteral iron or any recipients in the investigation drug&#xD;
             products&#xD;
&#xD;
          -  Erythropoietin treatment within 8 weeks prior to the screening visit&#xD;
&#xD;
          -  Other iron treatment or blood transfusion within 4 weeks prior to the screening visit&#xD;
&#xD;
          -  Planned elective surgery during the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut Faculty of Medicine</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 7, 2017</last_update_submitted>
  <last_update_submitted_qc>July 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Abbas</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrous fumarate</mesh_term>
    <mesh_term>Dextrans</mesh_term>
    <mesh_term>Iron-Dextran Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

